Abstract 562P
Background
Existing literature supports the principle of early detection of colorectal cancer (CRC) via screening but has not definitively demonstrated an association between colonoscopy or polypectomy rates and CRC stage over time.
Methods
A longitudinal study was performed using the Australian national health database to obtain colonoscopy and polypectomy rates between 1998-2017. A second prospective database of CRC resection specimens was analysed for this period. The cohort was divided into three based on time intervals related to the national bowel cancer screening program: pre-commencement 1998-2006 (Period A), immediately post-commencement 2007-2011 (Period B), and subsequent years 2012-2017 (Period C).
Results
Annual colonoscopy rates doubled, and polypectomy rates tripled during the study (p<0.001). A total of 4506 patients underwent colorectal cancer resections. Annual colonoscopy rate correlated to a lower T-stage (p=0.038) and lower N-stage (p=0.026) leading to a 7% absolute (13.4% relative) increase in early CRC (stage I-II) in Period C (p<0.001). Across the study there was also a significant increase in right-sided tumours, and concurrent MMR deficiency and BRAF mutation.
Conclusions
Polypectomy and colonoscopy rates increased after the introduction of a national screening program which correlated to a clinically relevant shift to earlier CRC stages, a reduction in CRC incidence which manifested five years after implementation, and a reduced need for adjuvant chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
622P - Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
Presenter: Marcel Reiser
Session: Poster session 10
623P - VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
Presenter: Yijiao Chen
Session: Poster session 10
624P - Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
Presenter: Meng Qiu
Session: Poster session 10
625P - Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Presenter: Claire Gallois
Session: Poster session 10
626P - Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
Presenter: Francisco Javier Ros Montana
Session: Poster session 10